Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Brain Neoplasms × sargramostim × Clear all

Phase

Status

Sponsor Class

OTHER 6 NETWORK 2 NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Leukemia, Myeloid, Acute 5 Glioblastoma 4 Breast Neoplasms 3 Pathologic Complete Response 2 Ovarian Neoplasms 2 Neoplasms 2 Multiple Myeloma 2 Melanoma 2 Lung Neoplasms 2 Gliosarcoma 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Wilms Tumor 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Smoldering Multiple Myeloma 1 Small Cell Lung Carcinoma 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Lymphoma, Follicular 1 Glioma 1 Brain Neoplasms 1 Advanced Ovarian Cancer 1 Advanced Cancer 1

Interventions

Temozolomide 25 Bevacizumab 13 Radiotherapy 11 Trastuzumab 10 Lomustine 9 Capecitabine 8 paclitaxel-Angiopep-2 conjugate 6 Radiation 5 Nivolumab 5 pembrolizumab 4 icotinib 4 dabrafenib 4 Lapatinib 4 Flucytosine 4 Dianhydrogalactitol 4 Corticotropin-Releasing Hormone 4 Chlorotoxin 4 vocimagene amiretrorepvec 3 tucatinib 3 osimertinib 3 motexafin gadolinium 3 abemaciclib 3 Surgical Procedures, Operative 3 Spermine Synthase 3 Radiosurgery 3 Paclitaxel 3 NVP-BKM120 3 Irinotecan 3 Gefitinib 3 Carboplatin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01480479 2018-01-16

ACT IV

Celldex Therapeutics

Phase 3 Completed

Brain Neoplasms, Glioblastoma, Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡